In Frontotemporal Dementia (FTD) age at disease onset (AAO) is unpredictable in both early and late-onset cases; AAO variability is found even in autosomal dominant FTD.
ABSTRACT
In Frontotemporal Dementia (FTD) age at disease onset (AAO) is unpredictable in both early and late-onset cases; AAO variability is found even in autosomal dominant FTD.
The present study was aimed at identifying genetic modifiers modulating AAO in a large cohort of Italian FTD patients.
We conducted an association analysis on 411 FTD patients, belonging to 7 Italian Centers, and for whom AAO was available. Population structure was evaluated by principal component analysis (PCA) to infer continuous axes of genetic variation, and single linear regression models were applied. A genetic Score (GS)
was calculated on the basis of suggestive Single Nucleotide Polymorphisms (SNPs) found by association analyses.
GS showed genome-wide significant slope decrease by -3.86 (95%CI: -4.64 to -3.07, p<2x10 -16 ) per standard deviation of the GS for 6 SNPs mapping to genes involved in neuronal development and signaling, axonal myelinization and glutamatergic/GABA neurotransmission. An increase of the GS was associated with a decrease of the AAO.
Our data indicate that there is indeed a genetic component that underpins and modulates up to 14.5% of variability of AAO in Italian FTD. Future studies on genetic modifiers in FTD are warranted.
Key words: GWAS; age at onset; Frontotemporal Dementia; polymorphism
INTRODUCTION
Frontotemporal Dementia (FTD) is a neurodegenerative disorder characterized by behavioural abnormalities, impairment of executive functions and language deficits [1] . Mutations in the Granulin (GRN), C9orf72 or Microtuble Associated Protein Tau (MAPT), and, recently, the TANK binding kinase 1 (TBK1) genes drive up to ~40% of Mendelian cases [2] ; for the remaining cases, multiple loci and genes appear to influence FTD risk with rather small effect size [3, 4] .
The clinical, pathological and genetic profiles, as well as the age at onset (AAO), are highly heterogeneous in FTD. FTD is considered the most common neurodegenerative dementia in the young adulthood along with Alzheimer Disease with a mean onset age between late 50s and early 60s [5] ; however, recent reports suggested an increased span in the range of disease onset up to >70 years of age [6, 7] . Similarly, variability of AAO is found in autosomal dominant FTD [8] [9] [10] [11] .
Genetic variants may influence and/or modulate specific features of a disorder, including disease onset and progression. Indeed, AAO, which is rather unpredictable in FTD, might associate with a genetic structure that contributes to an earlier or later disease development.
We recently carried out a Genome-Wide Association Study (GWAS) in FTD patients from Italy, and identified an extended number of genetic risk factors associated with disease in the Italian population [3] .
In the present work, we sought to explore whether such risk factors might influence disease onset in the Italian FTD population by searching for genetic variants associated with age at disease onset, and computing a genetic risk score (GS) to stratify age of disease susceptibility.
METHODS

Subjects.
Genotyping data of DNA samples diagnosed with FTD were available to us from the FTD-GWAS dataset (Ferrari et al., 2014) . Our association analysis was carried out on 411 FTD patients, belonging to 7 Italian Centres (see Supporting Table S1 ), already included in our previous study [3] and for whom AAO was available. Diagnosis of FTD, and FTD subtypes (i.e., behavioral variant FTD and Primary Progressive Aphasias), was made according to current clinical criteria [12, 13] . Estimated AAO was referred by the proxy caregiver by a semi-structured interview, and carefully recorded. . We defined SNPs as suggestive if 5×10 -5 > p> 5×10 -8 . We performed this analysis in presence and absence of apolipoprotein E (APOE) ɛ4 homozygous carriers and also used APOE ɛ4 as a covariate to assess and/or correct for any potential influence of this genetic marker on final results.
Genetic Score computation. The suggestive SNPs obtained by association analysis were used to calculate a weighted genetic risk score (GS). Specifically, GS was defined as sum of the number of minor frequency alleles (0 (not present), 1 (heterozygous), 2 (homozygous)) per suggestive SNPs weighted by their log OR, i.e. the odds ratio (OR) estimate derived from our previous case-control study [4] . Thus, the weights were determined independently from the genetic-AAO association of this work, eluding over fitting biases. We defined three trimming rules for inclusion of SNPs in the GS: 1) SNPs with moderate to high case-control signal (logORs >log(1.2)), recoding all negative logOR into positive logOR on the basis of the risk allele; 2)
SNPs observed or imputed with high quality (Rsq>0.9); and 3) SNPs in Linkage Equilibrium (LE). For SNPs in Linkage Disequilibrium, the SNP with the lowest AAO p-value was selected.
7
Then, GS was standardized as Z=(GS-mean(GS))/standard deviation (GS), and LRM of AAO on the standardized GS was performed adjusting for the following covariates: i) sex, ii) population structure (measured by geographical zone such as North, Centre, South and/or by significant principal components),
iii) type of FTD (5 subtypes: bvFTD, SD, PNFA, FTD-MND and FTD spectrum), and iv) APOE (0=e23e23, 1=e23e4, 2=e4e4).
QC analysis and statistical analyses were performed by free software PLINK [17] and R [18] , respectively.
Gene annotation on top-associated markers was performed by R package NCBI2R [19] . Population structure through PCA showed a genetic pattern that correlated with geographical provenience (i.e., North, Centre and South), as displayed in the scatter plot of the first two PCs (Fig. 1) .
According to Tracy-Widom statistics, tests of additional population structure of the first 10 eigenvalues, only the first PC (TW1=5.03480, P<0.001) was deemed significant and used as covariate in AAO association analyses to correct for population stratification.
By single linear regression analysis, we identified suggestive evidence (p<5x10 -5 ) of an association with AAO for 127 SNPs (using sex and first PC as covariates), while none achieved genome-wide significance (see Manhattan plot in Fig. 2 ).
As defined in the method section, log OR weighted genetic score (GS) was computed after three trimming rules identifying 6 SNPs mapping to the following loci: intergenic region on chromosome (chr) 1 encompassing the G protein-coupled receptor 137B (GPR137B) and the Endoplasmic Reticulum Oxidoreductase Beta (ERO1B) genes; chr 2, intronic to the Hypocalcin-like 1 (HPCAL1) gene and LOC730100
(which is proximal to Neurexin 1 (NRXN1)); chr 9, intronic to the Protein Tyrosine Phosphatase, Receptor
Type D (PTPRD) gene, and; chr 13, in LOC101926897, LOC105370219 and LOC105370220, and LOC105370290 and LINC00375 ( Table 1) .
Linear regression analysis of AAO based on the score effect of these 6 markers (GS), adjusted for covariates (see method), showed genome-wide significant slope decrease by -3.68 (95%CI: -4.52 to -2.84, p<2x10 -16 ) per standard deviation of the GS meaning that an increase of the GS was associated with a decrease of the AAO. When we excluded APOE ɛ4 homozygous carriers from our analysis still was a similar genome-wide significant slope decrease, and when using APOE ɛ4 as a covariate results were again not affected indicating that effect on AAO is independent from the APOE status. Of note, considering all the predictors (GS + covariates) we found that total contribution (R 2 ) to AAO variance was ~22% where only gender and PC1
were the actual significant covariates contributing to AAO variance in addition to GS of ~ 7%.
Therefore and in summary, the AAO variance explained by GS only (excluding the covariates) reached ~14.5%. The AAO-GS association is visualized and summarized in Fig. 3 and Table 2 , respectively. For overfitting control, we also computed the prediction error (PE) by Leave-One-Out method (K=n), and K=10-fold Cross-Validation: the corresponding R 2 were 13.7%, and 14.2%, respectively. Finally, backward stepwise analyses in the GS showed that 7.8% of this signal was driven by the AAO-associated SNPs in HPCAL1 and PTPRD.
DISCUSSION
FTD is a complex disorder that encompasses heterogeneous phenotypes and variable AAO. Our current study supports the notion that individual genetic background modifies age at disease onset and modulates disease presentation.
We computed a genetic score (GS) able to weight the genetic contribution to the variability of AAO in FTD (the higher the GS, the lower the age at disease onset). Particularly, the GS of six SNPs indicated significant genetic contribution for up to 14% of variability of AAO in FTD. This is remarkable as it suggests that the genetic component underlying variability of AAO has a robust implication in FTD comparatively, for example, to Parkinson's disease (PD) for which a similar study approach revealed that their GS only contributed to 0.6% of variability of AAO [20] . Similar observations for PD were made in other studies [21] .
Conversely, a recent study in Alzheimer's disease (AD) showed that either APOE or a combination of nine loci contributed to 3.7% and 2.2% of variability of AAO, respectively [22] , whereas in our current study the contribution of the APOE status was basically negligible. Taken all this together, we gather that in FTD the genetic component appears to have a stronger influence on AAO prediction than in PD and in AD [20, 21] .
Considering the 6 loci that we identified influencing AAO in FTD, the literature suggests, particularly for NRXN, HPCAL1, and PTPRD, a direct link with the biology of the brain through calcium-mediated neuronal signaling, development of neocortical regions as well as axonal myelination and glutamatergic/GABAergic synapsis, respectively [23] [24] [25] [26] . It is interesting to gather that variability in these genes, and their associated functions and processes, could underpin the modulation of disease onset in FTD. In addition, it is noteworthy that GPR137B was previously shown to associate with modulation of drug-response in schizophrenia, particularly mediating effect of antipsychotics on working memory [27] .
NRXN1 has been implicated in neocortical development and aging [23] , and NRXN1 genetic variations affect the risk of autism and schizophrenia [28, 29] . Of note, we reported the locus including NRXN1 already in our previous work highlighting novel suggestive loci for FTD in the Italian population (Ferrari et al., 2015) ; here, we provide further support for this association and expand on its potential implication in driving AAO. All the more, in the previous [3] and the current work, the OR associated with SNPs at the NRXN1 locus were among the highest, 2.5 and 1.64, respectively, suggesting that variability at this locus might associate with disease as well as AAO with a moderate effect size. Moreover, a close relationship between NRXN1 and one of the main actors of FTD pathogenesis, namely TDP-43 protein, was recently shown: a novel miRNA (miR-NID1) processed from the intron 5 of NRXN1 is able to repress NRXN1 expression by binding to TDP-43, thus this complex (TDP-43 + miR-NID1) might hold relevance and be implicated in FTD-TDP pathology [30] .
In the same view, HPCAL1, a gene encoding the HPCAL1 protein that modulates calcium-mediated neuronal signalling [25] , has been implicated in the risk of Alzheimer disease and autism development [31, 32] , thus supporting a general involvement in neurodegenerative disease, including FTD, and PTPRD has been associated with obsessive-compulsive disorders [26] . Currently, there are no known relationships with conditions affecting the brain for ERO1B (involved in protein oxidative folding) [33] , whilst the role of LOC101926897, LOC105370219 and LOC105370220, and LOC105370290 and LINC00375 appear to be more complicated to infer, given that the latter are non-coding RNAs, which belong to a different group of cellular functional elements, rather involved in transcription and/or translation regulation. Nevertheless, this piece of data raises the awareness that non-coding functional elements are important and deserve attention, fostering the implementation of study designs and analysis strategies that focus and shed light on such regulatory elements.
Our study overall suggest and supports the relevance of factors that modulate features of FTD; this goes along with other examples of common risk variants acting as genetic modifiers in Mendelian FTD such as TMEM106B. The latter has been reported as a genetic modifier affecting both AAO and circulating levels of progranulin in FTD patients carrying Granulin mutations [34, 35] . Another example of genetic modifiers of AAO is the one recently reported in PSEN1-related-AD [36] .
In summary, we herein describe an additive effect of six SNPs and their likely implication in modulating disease onset in Italian FTD patients, for which we further considered the genetic make-up of Italian regions (i.e. North, Centre and South) as possible confounder in the analyses, when a Mendelian trait was excluded a priori.
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Our data indicate that there is a genetic component that underpins and modulates up to 14.5% of variability of AAO in Italian FTD. 
